Vor Biopharma is a cell therapy company. Co.'s primary focus is on patients suffering from acute myeloid leukemia (AML). Co. develops treatments for patients suffering from hematological malignancies. Co. is developing its primary eHSC product candidate, VOR33, which it has potential to transform the treatment for AML and other blood cancers. CD33 is a clinically validated target for AML. Co. has initiated VBP101, a Phase 1/2a clinical trial in patients with CD33-positive AML who are at high risk of relapse. Co. is also developing its Treatment System comprising the VOR33-CLL1 multiplex-edited eHSC therapy and the VCAR33-CLL1 multi-specific CAR-T therapy. The VOR average annual return since 2021 is shown above.
The Average Annual Return on the VOR average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether VOR average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VOR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|